



CORPORATE NEWS

PERSONNEL CHANGES – SUPERVISORY BOARD

PAION AG: NEW SUPERVISORY BOARD MEMBER APPOINTED

Alan Goodman succeeds Prof Dr Erich Schlick

Aachen (Germany), 31 July 2008 - The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8, London AIM: PAI) today announces that the Court of Aachen followed a unanimous proposal by the Supervisory Board and Management Board of PAION to appoint Alan Goodman, CEO of Avlar BioVentures, to the Supervisory Board of PAION until the next General Meeting and effective as of 31 July 2008. Alan Goodman succeeds Prof Dr Erich Schlick who due to his responsibilities as a General Partner at a venture capital company with a growing portfolio resigned from his position effective as of 30 July 2008.

Alan Goodman was a chartered management accountant for many years and is the founder of a number of biotech companies including CeNeS pharmaceuticals plc which was acquired by PAION in June 2008. He is also founder of Avlar BioVentures, a venture capital fund that invests in early stage life science companies. Through the fund he was invested in CeNeS Pharmaceuticals plc, as was his private investment vehicle ATM Investments Ltd. In addition, he was also a private investor in CeNeS Pharmaceuticals plc. As a consequence, he is a direct and indirect investor in PAION, too. At the time of the acquisition, he was Chairman of CeNeS Pharmaceuticals plc.

Dr Walter Wenninger, Chairman of PAION AG's Supervisory Board commented: *"Alan Goodman is recognized as a leading biotechnology entrepreneur and has been a long-term supporter of former CeNeS. We are very pleased that he was now appointed to the Supervisory Board of PAION. We would also like to thank Prof Schlick who has made important contributions to the development of PAION based on his expertise in drug development as well as in financing."*

Prof Schlick supported PAION since 2003, first as a member of the Advisory Board and later as a member of the Supervisory Board. He is a General Partner in the life science team of Wellington Partners Venture Capital GmbH, Munich, Germany.

###

About PAION

PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals, which was completed in June 2008, the company has a second site in Cambridge, UK. The company is specializing in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need. PAION intends to further expand its portfolio of drugs by

exploiting its core expertise in identifying high-potential compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process. Where appropriate, particularly during the late stages of the clinical development and approval process and the commercialization phase, PAION seeks to collaborate with experienced partners.

Contact

Dr. Peer Nils Schröder, Corporate Communications & Investor Relations

PAION AG

Martinstrasse 10-12

52062 Aachen - Germany

Phone +49 241 4453-152

E-mail pn.schroeder@paion.de

www.paion.de

Landsbanki Securities (UK) Limited

Nomad and broker

Shaun Dobson/Claes Spång

Phone +44 20 7426 9000